BRIEF-Krystal Biotech’S Kb103 Receives Orphan Medicinal Product Designation In Europe For Dystrophic Epidermolysis Bullosa
April 19, 2018 at 08:04 AM EDT
* KRYSTAL BIOTECH’S KB103 RECEIVES ORPHAN MEDICINAL PRODUCT DESIGNATION IN EUROPE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:
